IMRT planning studies for dose escalation to 80.5 Gy with locally advanced head and neck tumors - Preparations for dose specification for a new German multi-center study with DFG funding

被引：0

作者：

Schill, S. ^{[1
]}

Pigorsch, S. ^{[1
]}

机构：

[1] Tech Univ Munich, Klinikum Rechts Isar, Klin & Poliklin Strahlentherapie & Radiol Onkol, Munich, Germany

来源：

STRAHLENTHERAPIE UND ONKOLOGIE | 2009年 / 185卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：92 / 92

页数：1

共 18 条

[11] A phase 1, multi-center, open-label, dose-escalation, and dose-expansion study of CBP-1018, a bi-ligand-drug conjugate in patients with heavily treated advanced solid tumors.
Li, Kaiwen
Wu, Junyan
Ye, Suiwen
Liu, Yanqiong
Huang, Hao
Fan, Fan
Lai, Yiming
Zhuang, Suili
Zhou, Liyan
Huang, Robert
Xu, Mo
Pan, Bin
Zhang, Jian
Shi, Yehui
Huang, Hai
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[12] SQ3370-001 IS A MULTI-CENTER OPEN-LABEL PHASE I DOSE-ESCALATION STUDY TO TEST A NOVEL INTRATUMORAL AND SYSTEMIC APPROACH TO TREAT ADVANCED SOLID TUMORS
Bhadri, Vivek
Bui, Nam
Guminski, Alexander
Oneto, Jose Mejia
Murthy, Ravi
Sankhala, Kamalesh
Saville, M. Wayne
Srinivasan, Sangeetha
Steffner, Robert
Subbiah, Vivek
Wang, Ding
Yee, Nathan
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A253 - A254
[13] A phase I study of the CDK4/6 inhibitor, palbociclib in combination with cetuximab and intensity modulated radiation therapy (IMRT) for locally advanced squamous cell carcinoma of the head and neck (SCCHN); A result of dose escalation cohort
Ngamphaiboon, N.
Jiarpinitnun, C.
Siripoon, T.
Lukerak, S.
Jinawath, A.
Jinawath, N.
Arsa, L.
Konmun, J.
Kongsuphon, N.
Sankaseam, N.
Sirachainan, E.
Witoonpanich, P.
Kositwattanarerk, A.
Pattaranutaporn, P.
ANNALS OF ONCOLOGY, 2019, 30 : 456 - 456
[14] A Phase 1, Multi-Center, Open-Label, Dose De-Escalation Study of the Oncolytic Virus Talimogene Laherparepvec (T-VEC) in Paediatric Patients with Advanced Extracranial Solid Tumors
Moreno, L.
Zhang, Y.
Bhatta, S.
PEDIATRIC BLOOD & CANCER, 2016, 63 : S211 - S211
[15] A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma
Cheng, A-L.
Yen, C-J.
Okusaka, T.
Ikeda, M.
Hsu, C-H.
Wu, S-Y.
Morizane, C.
Hashimoto, Y.
Ueshima, K.
Ohtomo, T.
Tanaka, T.
Kudo, M.
ANNALS OF ONCOLOGY, 2018, 29
[16] KontRASt: A Phase Ib/II, open-label, multi-center, dose-escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation
Solomon, Benjamin
Heist, Rebecca S.
Tan, Daniel S. W.
Cassier, Philippe A.
Dooms, Christophe
Van Cutsem, Eric
Steuer, Conor E.
Steeghs, Neeltje
Schuler, Martin
Gazzah, Anas
Wermke, Martin
Felip, Enriqueta
Loong, Herbert H. F.
Luken, Maria J. De Miguel
Soo, Ross A.
Jaeger, Ashley
Xu, Kun
Chen, Xueying
Cui, Xiaoming
Burks, Heather
Farago, Anna F.
Shimizu, Toshio
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
[17] A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumors
Bauer, S.
Demetri, G.
Jeay, S.
Dummer, R.
Guerreiro, N.
Tan, D. S.
Kumar, A.
Meille, C.
Van Bree, L.
Halilovic, E.
Wuerthner, J. U.
Cassier, P.
ANNALS OF ONCOLOGY, 2016, 27
[18] MP0274-CP101: A phase 1, first-in-human, single-arm, multi-center, open-label, dose escalation study to assess safety, tolerability, and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors
Baird, Richard
Omlin, Aurelius
Kiemle-Kallee, Joachim
Fiedler, Ulrike
Zitt, Christof
Feurstein, Daniel
Herbst, Joerg
Dawson, Keith
vom Baur, Elmar
Stumpp, Michael
Hermann, Frank
Harstrick, Andreas
Schneeweiss, Andreas
CANCER RESEARCH, 2018, 78 (04)

← 1 2 →